Screener
Jazz Pharmaceuticals JAZZ Proceeds from sale of assets
Proceeds from sale of assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by operating activities | 408.2 | 429.8 |
| Investing activities | ||
| Proceeds from maturity of investments | 520.0 | 310.0 |
| Proceeds from sale of priority review voucher | 200.0 | — |
| Payments related to sale of priority review voucher | (77.2) | — |
| Purchases of property, plant and equipment | (19.7) | (13.9) |
| Acquisition of investments | (500.0) | (440.1) |
| Acquisition of intangible assets | — | (25.0) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's proceeds from sale of assets?
- Jazz Pharmaceuticals (JAZZ) reported proceeds from sale of assets of $200M in Q1 2026.
- What does proceeds from sale of assets mean?
- Cash inflows resulting from the divestiture of non-core or redundant physical and intangible assets. This provides insight into the company's ability to monetize assets that no longer align with its strategic objectives.
Ask your AI about Jazz Pharmaceuticals's proceeds from sale of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude